Data last updated: Oct 23, 2026, 5:45 PM ETLatest filing: Oct 22, 2026Now: Oct 24, 2026, 3:54 AM ET

Sponsor Check › Person

Jonathan Fleming

Named as an officer, director or promoter on SEC Form D filings · MA · Jan 11, 2010 → Oct 21, 2026

15deals (issuers)

$507.8Mreported sold

461investors

31Form D filings

2010–2026years on file

Follow this person Look further ↓PDF

Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 2:20 AM ET · SEC enforcement last checked: Oct 24, 2026, 2:39 AM ET

The short version

Jonathan Fleming is listed as an executive officer and director on 31 SEC Form D filings by 15 issuers between Jan 2010 and Oct 2026. Largest by amount reported sold: Radius Health, Inc. (Cambridge, MA — pharmaceuticals — 2011; $126.9M reported sold to 36 investors), Greenlight Biosciences Inc. (Medford, MA — other technology — 2013–2017; $102.5M reported sold to 19 investors), SQZ Biotechnologies Co (Watertown, MA — biotechnology — 2015–2020; $71.3M reported sold to 48 investors), Q-State Holdings, Inc. (Cambridge, MA — biotechnology — 2018; $64.8M reported sold to 51 investors), QurAlis Corp (Cambridge, MA — pharmaceuticals — 2020; $60M reported sold to 27 investors) and 10 more (all listed below).

What this means That is a lot of deals — 15 separate companies raised money with this person listed as executive officer and director, over about 16 years. Across those companies the filings report $507.8M sold in total.

Listed alongside Amy Schulman (7 shared filings), Armon Sharei, Ph.D. (6 shared filings), Klavs F. Jensen, Ph.D. (6 shared filings), Andrey Zarur (4 shared filings), Charles Cooney (4 shared filings) and 116 others.

What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Jonathan. Each name links to their own page.

The issuers belong to 2 sponsor groups: Greenlight (2 issuers, $111.3M reported sold, 2013–2020) and Q State (2 issuers, $23.2M reported sold, 2018–2020).

What this means This person is listed across more than one sponsor team; each group page shows that team's full track record.

Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — 9 bankruptcy cases matching the name listed in Key records below.

What this means 9 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.

What the community is saying

Nothing found on Reddit, BiggerPockets or community forums for high-net-worth investors (searched Oct 24, 2026) — search queued; this line updates when it has run.

Community comments are quoted as written by their authors. Sources searched: BiggerPockets forums (via DuckDuckGo, Brave, Bing and BiggerPockets search) and Reddit (search feed + public archive).

Key records

Five things investors ask first. Items still in human review are counted, not shown.

1. Lawsuits

None found in sources searched

What was searched

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts; live RECAP re-check pending. State courts: not yet searched. PACER: not searched. · Last checked Oct 24, 2026, 2:20 AM ET.

State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

None found in sources searched

What was searched

SEC enforcement searched: SEC litigation releases + SEC administrative proceedings (sec.gov index, 1995-09-19 → 2026-10-23) — last checked Oct 24, 2026, 2:39 AM ET.

State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.

3. Bankruptcies

9 cases: 2 open, 7 closed (disposition not in docket feed)

Jonathan Fleming open

United States Bankruptcy Court, W.D. New York · No. 2-26-20012 · Filed Jan 8, 2026

Role of Jonathan Fleming: Debtor · Outcome: Pending — no termination date on the docket (bulk snapshot 2026-09-30) Docket on CourtListener ↗

same full name (a name found in 17 federal dockets); 3 people with this name in Form D filings; court in NY (not a filing state)

Jonathan L Fleming open

United States Bankruptcy Court, M.D. Georgia · No. 20-70375 · Filed Apr 8, 2020

Role of Jonathan L Fleming: Debtor · Outcome: Pending — no termination date on the docket (bulk snapshot 2026-09-30) Docket on CourtListener ↗

same full name (a name found in 17 federal dockets); 3 people with this name in Form D filings; court in GA (not a filing state)

Jonathan P. Fleming and Amber L. Fleming closed

United States Bankruptcy Court, E.D. Wisconsin · No. 18-29157 · Filed Sep 25, 2018 · Closed Jan 28, 2019

Role of Jonathan P. Fleming and Amber L. Fleming: Debtor · Outcome: Case closed 2019-01-28 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗

same full name (a name found in 17 federal dockets); 3 people with this name in Form D filings; court in WI (not a filing state)

Jonathan Fleming closed

United States Bankruptcy Court, E.D. Virginia · No. 13-30822 · Filed Feb 19, 2013 · Closed May 28, 2013

Role of Jonathan Fleming: Debtor · Outcome: Case closed 2013-05-28 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗

same full name (a name found in 17 federal dockets); 3 people with this name in Form D filings; court in VA (not a filing state)

Jonathan P Fleming and DeAnna Fleming closed

United States Bankruptcy Court, N.D. Alabama · No. 09-84141 · Filed Oct 11, 2009 · Closed Jan 11, 2010

Role of Jonathan P Fleming and DeAnna Fleming: Debtor · Outcome: Case closed 2010-01-11 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗

same full name (a name found in 17 federal dockets); 3 people with this name in Form D filings; court in AL (not a filing state)

Jonathan D Fleming and Ann M Fleming closed

United States Bankruptcy Court, N.D. Ohio · No. 06-33377 · Filed Nov 20, 2006 · Closed Apr 12, 2007

Role of Jonathan D Fleming and Ann M Fleming: Debtor · Outcome: Case closed 2007-04-12 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗

same full name (a name found in 17 federal dockets); 3 people with this name in Form D filings; court in OH (not a filing state)

Jonathan C Fleming and D'neydra C Fleming closed

United States Bankruptcy Court, M.D. Florida · No. 3:05-bk-15579 · Filed Oct 14, 2005 · Closed Dec 3, 2007

Role of Jonathan C Fleming and D'neydra C Fleming: Debtor · Outcome: Case closed 2007-12-03 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗

same full name (a name found in 17 federal dockets); 3 people with this name in Form D filings; court in FL (not a filing state)

Jonathan Fleming closed

United States Bankruptcy Court, E.D. Pennsylvania · No. 01-25268 · Filed Nov 19, 2001 · Closed Mar 14, 2002

Role of Jonathan Fleming: Debtor · Outcome: Case closed 2002-03-14 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗

same full name (a name found in 17 federal dockets); 3 people with this name in Form D filings; court in PA (not a filing state)

Jonathan Fleming closed

United States Bankruptcy Court, N.D. Indiana · No. 01-64130 · Filed Sep 28, 2001 · Closed Jul 22, 2002

Role of Jonathan Fleming: Debtor · Outcome: Case closed 2002-07-22 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗

same full name (a name found in 17 federal dockets); 3 people with this name in Form D filings; court in IN (not a filing state)

What was searched

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:20 AM ET.

Court records show docket facts only; we never restate allegations as facts. Outcome wording comes from the docket feed; where it does not state a disposition we say so.

4. Differences between public sources

Not made for individual people — comparisons cover issuers and sponsor groups

5. Money to insiders

2 of 25 offerings report sales commissions totalling $1,237,368; 0 report finder's fees; 5 report proceeds to related persons totalling $4,316,487. (includes amounts the issuer reported as estimates)

Offering (latest filing)	Sales commissions	Finder's fees	To insiders	Paid to sell it	Source
Oct 21, 2026 D Quiver Holdings Inc. File 021-601971	$0	$0	$0 None, other than ordinary compensation and director fees.	None listed on this filing	EDGAR ↗
Aug 5, 2024 D/A Diceros Therapeutics, Inc. File 021-460347	$0	$0	$1,038,035	None listed on this filing	EDGAR ↗
Mar 1, 2024 D EnClear Therapies, Inc. File 021-506508	$0	$0	$0	None listed on this filing	EDGAR ↗
Jan 12, 2024 D Aquacultural Research Corp File 021-502312	$0	$0	$2 (est.) Repayment of convertible notes.	None listed on this filing	EDGAR ↗
Jun 1, 2020 D SQZ Biotechnologies Co File 021-368023	$0	$0	$0	None listed on this filing	EDGAR ↗
May 18, 2020 D QurAlis Corp File 021-367164	$0	$0	$0	None listed on this filing	EDGAR ↗
Nov 25, 2019 D SQZ Biotechnologies Co File 021-354117	$0	$0	$0	None listed on this filing	EDGAR ↗
Sep 11, 2019 D Continuus Pharmaceuticals, Inc. File 021-348478	$0	$0	$0	None listed on this filing	EDGAR ↗
Jun 25, 2019 D Aquacultural Research Corp File 021-342750	$0	$0	$103,450 (est.) Repayment of promissory note.	None listed on this filing	EDGAR ↗
Oct 25, 2018 D Q-State Holdings, Inc. File 021-324311	$0	$0	$0	None listed on this filing	EDGAR ↗
Sep 14, 2017 D Greenlight Biosciences Inc. File 021-294749	$0	$0	$0	None listed on this filing	EDGAR ↗
Dec 1, 2016 D/A SQZ Biotechnologies Co File 021-271785	$0	$0	$0	None listed on this filing	EDGAR ↗
Aug 27, 2015 D Aquacultural Research Corp File 021-246520	$0	$0	$0	None listed on this filing	EDGAR ↗
Jul 28, 2015 D/A SQZ Biotechnologies Co File 021-242788	$0	$0	$0	None listed on this filing	EDGAR ↗
Jun 16, 2015 D Greenlight Biosciences Inc. File 021-241858	$0	$0	$675,000 (est.) The Issuer expects to pay approximately $675,000 of the gross proceeds to related persons as compensation, including benefits, over the course of one year.	None listed on this filing	EDGAR ↗
Jun 25, 2014 D Continuus Pharmaceuticals, Inc. File 021-219828	$0	$0	$0	None listed on this filing	EDGAR ↗
Jan 6, 2014 D RAILRUNNER NA INC File 021-209333	$0	$0	$0	None listed on this filing	EDGAR ↗
Dec 20, 2013 D/A Greenlight Biosciences Inc. File 021-201107	$0	$0	$0	None listed on this filing	EDGAR ↗
Jan 6, 2012 D/A AVAXIA BIOLOGICS, Inc File 021-168953	$0	$0	$0	None listed on this filing	EDGAR ↗
May 31, 2011 D Radius Health, Inc. File 021-160578	$434,868	$0	$0	Leerink Swann LLC BrokerCheck CRD 39011 ↗ via Leerinks Swann LLC (CRD 39011 ↗)	EDGAR ↗
May 31, 2011 D Radius Health, Inc. File 021-160580	$0	$0	$0	None listed on this filing	EDGAR ↗
Jun 10, 2010 D Rib-X Pharmaceuticals, Inc. File 021-143283	$0	$0	$0 (est.)	None listed on this filing	EDGAR ↗
Apr 14, 2010 D HYDROCISION INC File 021-140572	$0	$0	$0	None listed on this filing	EDGAR ↗
Feb 22, 2010 D RAILRUNNER NA INC File 021-76309	$802,500 (est.)	$0	$0	U.S. Boston Capital Corporation no CRD number reported	EDGAR ↗
Feb 4, 2010 D/A MOLECULAR BIOMETRICS INC File 021-123566	$0	$0	$2,500,000 (est.)	None listed on this filing	EDGAR ↗

How this is counted

Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

Counted across every filing this person is listed on (latest filing per offering, per issuer).

Deals 15

Every issuer that named Jonathan Fleming on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.

Biotechnology

Quiver Holdings Inc.

Cambridge, MA · Oct 21, 2026

Oct 21, 2026 · D · $3,005,000 sold of Indefinite · 4 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $3M from 4 investors as of the latest filing. Jonathan is listed as director.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Biotechnology

Diceros Therapeutics, Inc.

Newton, MA · Sep 30, 2022 → Aug 5, 2024 · 2 filings

Aug 5, 2024 · D/A · $12,609,962 sold of $18,069,960 · 13 investors · min. No minimum reported · role: Director EDGAR ↗
Sep 30, 2022 · D · $6,679,992 sold of $16,699,979 · 13 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $12.6M from 13 investors (70% of the $18.1M target) as of the latest filing. Jonathan is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗

Sources

Other

EnClear Therapies, Inc.

Cambridge, MA · Mar 1, 2024

Mar 1, 2024 · D · $718,331 sold of $1,999,996 · 8 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $718K from 8 investors (36% of the $2M target) as of the latest filing. Jonathan is listed as director.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other / 506(b) (18,678 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Other

Aquacultural Research Corp

Dennis, MA · Aug 27, 2015 → Jan 12, 2024 · 3 filings

Jan 12, 2024 · D · $1,229,169 sold of $1,500,000 · 17 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
Jun 25, 2019 · D · $428,368 sold of $977,460 · 8 investors · min. $5,000 · role: Director EDGAR ↗
Aug 27, 2015 · D · $1,626,000 sold of $1,626,000 · 17 investors · min. $25,000 · role: Director EDGAR ↗

Raised $1.63M from 17 investors (100% of the $1.5M target) as of the latest filing. Jonathan is listed as executive officer, director on 3 filings for this deal.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other / 506(b) (18,678 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Biotechnology

SQZ Biotechnologies Co

Watertown, MA · Jun 30, 2015 → Jun 1, 2020 · 6 filings

Jun 1, 2020 · D · $66,253,006 sold of $70,203,000 · 27 investors · min. No minimum reported · role: Director EDGAR ↗
Nov 25, 2019 · D · $71,253,215 sold of Indefinite · 48 investors · min. No minimum reported · role: Director EDGAR ↗
Dec 1, 2016 · D/A · $24,061,840 sold of $24,061,840 · 34 investors · min. No minimum reported · role: Director EDGAR ↗
Oct 4, 2016 · D · $15,739,913 sold of $15,739,913 · 26 investors · min. No minimum reported · role: Director EDGAR ↗
Jul 28, 2015 · D/A · $5,081,019 sold of $5,081,019 · 24 investors · min. No minimum reported · role: Director EDGAR ↗
Jun 30, 2015 · D · $5,011,019 sold of $5,011,019 · 22 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $71.3M from 48 investors (100% of the $70.2M target) as of the latest filing. Jonathan is listed as director on 6 filings for this deal.

Latest filing on EDGAR ↗

Sources

Pharmaceuticals

QurAlis Corp

Cambridge, MA · May 18, 2020

May 18, 2020 · D · $33,222,703 sold of $60,000,000 · 25 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $60M from 27 investors (100% of the $60M target) as of the latest filing. Jonathan is listed as director.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Pharmaceuticals

Continuus Pharmaceuticals, Inc.

Woburn, MA · Jun 25, 2014 → Sep 11, 2019 · 2 filings

Sep 11, 2019 · D · $5,000,041 sold of $5,000,041 · 20 investors · min. No minimum reported · role: Director EDGAR ↗
Jun 25, 2014 · D · $2,463,659 sold of $2,600,000 · 15 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $5M from 20 investors (100% of the $5M target) as of the latest filing. Jonathan is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Biotechnology · group: Q State

Q-State Holdings, Inc.

Cambridge, MA · Oct 25, 2018

Oct 25, 2018 · D · $64,831,545 sold of $66,631,545 · 51 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗

Raised $64.8M from 51 investors (97% of the $66.6M target) as of the latest filing. Jonathan is listed as executive officer, director.

Latest filing on EDGAR ↗

Sources

Other Technology · group: Greenlight

Greenlight Biosciences Inc.

Medford, MA · Aug 9, 2013 → Sep 14, 2017 · 4 filings

Sep 14, 2017 · D · $9,999,995 sold of $18,000,000 · 10 investors · min. No minimum reported · role: Director EDGAR ↗
Jun 16, 2015 · D · $20,007,507 sold of $20,007,507 · 7 investors · min. $91,000 · role: Director EDGAR ↗
Dec 20, 2013 · D/A · $8,045,815 sold of $8,045,815 · 3 investors · min. No minimum reported · role: Director EDGAR ↗
Aug 9, 2013 · D · $7,000,000 sold of $7,000,000 · 2 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $102.5M from 19 investors (100% of the $18M target) as of the latest filing. Jonathan is listed as director on 4 filings for this deal.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Technology / 506(b) (17,390 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Other

RAILRUNNER NA INC

Lexington, MA · Feb 22, 2010 → Jan 6, 2014 · 2 filings

Jan 6, 2014 · D · $6,082,611 sold of $6,082,611 · 10 investors · min. No minimum reported · role: Director EDGAR ↗
Feb 22, 2010 · D · $13,375,000 sold of $13,375,000 · 1 investors · min. $100,000 · role: Director EDGAR ↗

Raised $13.4M from 10 investors (100% of the $6.08M target) as of the latest filing. Jonathan is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other / 506(b) (18,678 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Other Health Care

AVAXIA BIOLOGICS, Inc

Lexington, MA · Nov 18, 2011 → Jan 6, 2012 · 2 filings

Jan 6, 2012 · D/A · $3,443,378 sold of $4,460,000 · 94 investors · min. No minimum reported · role: Director EDGAR ↗
Nov 18, 2011 · D · $2,281,339 sold of $4,460,000 · 48 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $11.5M from 164 investors (100% of the $4.46M target) as of the latest filing. Jonathan is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

Pharmaceuticals

Radius Health, Inc.

Cambridge, MA · May 31, 2011 → May 31, 2011 · 2 filings

May 31, 2011 · D · $126,880,217 sold of $126,880,217 · 36 investors · min. No minimum reported · role: Director (Mr. Fleming is a director of the Issuer.) EDGAR ↗
May 31, 2011 · D · $64,285,446 sold of $64,285,446 · 18 investors · min. No minimum reported · role: Director (Mr. Fleming is a director of the Issuer.) EDGAR ↗

Raised $126.9M from 36 investors (100% of the $126.9M target) as of the latest filing. Jonathan is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

Pharmaceuticals

Rib-X Pharmaceuticals, Inc.

New Haven, CT · Jun 10, 2010

Jun 10, 2010 · D · $5,500,000 sold of $15,000,000 · 16 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $18.7M from 16 investors (100% of the $15M target) as of the latest filing. Jonathan is listed as director.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

Biotechnology

HYDROCISION INC

North Billerica, MA · Apr 14, 2010

Apr 14, 2010 · D · $623,635 sold of $700,000 · 8 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $3.02M from 12 investors (100% of the $700K target) as of the latest filing. Jonathan is listed as director.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

Biotechnology

MOLECULAR BIOMETRICS INC

Norwood, MA · Jan 11, 2010 → Feb 4, 2010 · 2 filings

Feb 4, 2010 · D/A · $12,755,376 sold of $16,961,567 · 16 investors · min. $2 · role: Director EDGAR ↗
Jan 11, 2010 · D · $12,500,000 sold of $16,961,567 · 4 investors · min. $2 · role: Director EDGAR ↗

Raised $12.8M from 16 investors (75% of the $17M target) as of the latest filing. Jonathan is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

Other pages with the same name (2)

Separate person records under the same name, not combined with this page. Each line says whether it shares an issuer with this record.

Jonathan Fleming — CA, 2 issuers, Jul 1, 2013 → Dec 2, 2020 · no shared issuer
Jonathan J. Fleming — OH, 1 issuer, May 14, 2009 → May 10, 2010 · no shared issuer

People around Jonathan 40

Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET. Showing the 40 with the most shared filings.

Person

Amy Schulman

Director, Executive Officer · 7 shared filings (2 issuers) · also on 18 other issuers

Amy Schulman is on 20 issuers in total — a repeat sponsor. Their page lists every one.

Person

Armon Sharei, Ph.D.

Executive Officer, Director · 6 shared filings (1 issuer)

Listed on the same filings as Jonathan Fleming. Their page shows their other deals.

Person

Klavs F. Jensen, Ph.D.

Director · 6 shared filings (1 issuer)

Listed on the same filings as Jonathan Fleming. Their page shows their other deals.

Person

David Furneaux

Director · 4 shared filings (1 issuer) · also on 8 other issuers

David Furneaux is on 9 issuers in total — a repeat sponsor. Their page lists every one.

Person

Neil Renninger

Director · 4 shared filings (1 issuer) · also on 3 other issuers

Listed on the same filings as Jonathan Fleming. Their page shows their other deals.

Person

Andrey Zarur

Executive Officer, Director · 4 shared filings (1 issuer) · also on 7 other issuers

Andrey Zarur is on 8 issuers in total — a repeat sponsor. Their page lists every one.

Person

James Swartz

Director · 4 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Jonathan Fleming. Their page shows their other deals.

Person

Charles Cooney

Director · 4 shared filings (1 issuer) · also on 7 other issuers

Charles Cooney is on 8 issuers in total — a repeat sponsor. Their page lists every one.

Person

Eric Moessinger

Director · 4 shared filings (1 issuer) · also on 7 other issuers

Eric Moessinger is on 8 issuers in total — a repeat sponsor. Their page lists every one.

Person

Robert Ackerman

Director · 3 shared filings (1 issuer) · also on 5 other issuers

Robert Ackerman is on 6 issuers in total — a repeat sponsor. Their page lists every one.

Person

Sara Wilson

Director · 3 shared filings (1 issuer)

Listed on the same filings as Jonathan Fleming. Their page shows their other deals.

Person

Dale Leavitt

Director · 3 shared filings (1 issuer)

Listed on the same filings as Jonathan Fleming. Their page shows their other deals.

Person

John Pappalardo

Director · 3 shared filings (1 issuer)

Listed on the same filings as Jonathan Fleming. Their page shows their other deals.

Person

Mary Beth Daniel

Director · 3 shared filings (1 issuer)

Listed on the same filings as Jonathan Fleming. Their page shows their other deals.

Person

Garry A. Nicholson

Director · 3 shared filings (1 issuer) · also on 5 other issuers

Garry A. Nicholson is on 6 issuers in total — a repeat sponsor. Their page lists every one.

Person

Kurt Graves

Director, Promoter · 2 shared filings (1 issuer) · also on 6 other issuers

Kurt Graves is on 7 issuers in total — a repeat sponsor. Their page lists every one.

Person

Ansbert Gadicke

Director, Promoter · 2 shared filings (1 issuer) · also on 20 other issuers

Ansbert Gadicke is on 21 issuers in total — a repeat sponsor. Their page lists every one.

Person

Peter Barrett

Director · 2 shared filings (1 issuer) · also on 11 other issuers

Peter Barrett is on 12 issuers in total — a repeat sponsor. Their page lists every one.

Person

Darius Gaskins

Director · 2 shared filings (1 issuer)

Listed on the same filings as Jonathan Fleming. Their page shows their other deals.

Person

Charles Foskett

Executive Officer, Director · 2 shared filings (1 issuer)

Listed on the same filings as Jonathan Fleming. Their page shows their other deals.

Person

Matthew Whiten

Executive Officer · 2 shared filings (1 issuer)

Listed on the same filings as Jonathan Fleming. Their page shows their other deals.

Person

Daniel Renzella

Executive Officer · 2 shared filings (1 issuer)

Listed on the same filings as Jonathan Fleming. Their page shows their other deals.

Person

James Posillico

Executive Officer, Director · 2 shared filings (1 issuer)

Listed on the same filings as Jonathan Fleming. Their page shows their other deals.

Person

Bruce Goldstein

Executive Officer · 2 shared filings (1 issuer)

Listed on the same filings as Jonathan Fleming. Their page shows their other deals.

Person

Edward L. Erickson

Director · 2 shared filings (1 issuer) · also on 3 other issuers

Listed on the same filings as Jonathan Fleming. Their page shows their other deals.

Person

Ganesh Kishore

Director · 2 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as Jonathan Fleming. Their page shows their other deals.

Person

HOWARD BERNSTEIN

Executive Officer · 2 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as Jonathan Fleming. Their page shows their other deals.

Person

Robert Langer, Sc.D.

Director · 2 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Jonathan Fleming. Their page shows their other deals.

Person

Stephen R. Seiler

Executive Officer, Director · 2 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Jonathan Fleming. Their page shows their other deals.

Person

Alan Auerbach

Director, Promoter · 2 shared filings (1 issuer)

Listed on the same filings as Jonathan Fleming. Their page shows their other deals.

Person

Elizabeth Stoner

Director, Promoter · 2 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as Jonathan Fleming. Their page shows their other deals.

Person

C. Richard Lyttle

Executive Officer, Director, Promoter · 2 shared filings (1 issuer)

Listed on the same filings as Jonathan Fleming. Their page shows their other deals.

Person

Louis O'Dea

Executive Officer, Promoter · 2 shared filings (1 issuer)

Listed on the same filings as Jonathan Fleming. Their page shows their other deals.

Person

Gary Hattersley

Executive Officer, Promoter · 2 shared filings (1 issuer)

Listed on the same filings as Jonathan Fleming. Their page shows their other deals.

Person

Martin Muenchbach

Director, Promoter · 2 shared filings (1 issuer)

Listed on the same filings as Jonathan Fleming. Their page shows their other deals.

Person

B. Nicholas Harvey

Executive Officer, Promoter · 2 shared filings (1 issuer)

Listed on the same filings as Jonathan Fleming. Their page shows their other deals.

Person

Barbara S. Fox

Executive Officer, Director · 2 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Jonathan Fleming. Their page shows their other deals.

Person

Eileen F. Bostwick

Executive Officer · 2 shared filings (1 issuer)

Listed on the same filings as Jonathan Fleming. Their page shows their other deals.

Person

David C. Dlesk

Executive Officer · 2 shared filings (1 issuer)

Listed on the same filings as Jonathan Fleming. Their page shows their other deals.

Person

David Poorvin

Executive Officer, Director · 2 shared filings (1 issuer)

Listed on the same filings as Jonathan Fleming. Their page shows their other deals.

The team behind the deals

Sponsor group

Greenlight

2 issuers · 7 filings · $111.3M reported sold · 2013–2020

GB Greenlight Biosciences Inc. Other Technology · $102.5M sold · 2013 · listed
GP GreenLight Pandemic Response, Inc. Other Technology · $8.78M sold · 2020

One team, 2 deal companies. Jonathan Fleming is listed on 1 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Jonathan Fleming.

Sponsor group

Q State

2 issuers · 3 filings · $23.2M reported sold · 2018–2020

QS Q-State Holdings, Inc. Biotechnology · $64.8M sold · 2018 · listed
QS Q-State PainCo, Inc. Biotechnology · $2M sold · 2018

One team, 2 deal companies. Jonathan Fleming is listed on 1 of them.

Sources

Same business address

28 other issuers file from the same address

Tinos Therapeutics, Inc. Cambridge, MA · 2025
Amaryllis Therapeutics, Inc. Cambridge, MA · 2024
Eye Care International LLC Cambridge, MA · 2023
Myrobalan Therapeutics Holding, Inc. Medford, MA · 2024
March Therapeutics, Inc. Cambridge, MA · 2020
Syros Pharmaceuticals, Inc. Cambridge, MA · 2012
Kelonia Therapeutics, Inc. Cambridge, MA · 2022
New Equilibrium Biosciences, Inc. Cambridge, MA · 2020
Satellite Biosciences, Inc. Cambridge, MA · 2020
Kernal Biologics, Inc. Cambridge, MA · 2016
Travera, Inc. Medford, MA · 2018
Sofregen Medical Inc. Medford, MA · 2016
Q-State PainCo, Inc. Cambridge, MA · 2018
SEVENTH SENSE BIOSYSTEMS, INC. Medford, MA · 2010
ReviveMed, Inc. Cambridge, MA · 2018
MELINTA THERAPEUTICS, INC. /NEW/ New Haven, CT · 2009
LogicBio Therapeutics, Inc. Cambridge, MA · 2016
Ascendance Biotechnology, Inc. Medford, MA · 2015
AFFINIMARK TECHNOLOGIES INC New Haven, CT · 2010
Microchips Biotech, Inc. Lexington, MA · 2009
KOLLTAN PHARMACEUTICALS INC New Haven, CT · 2009
SYNAGEVA BIOPHARMA CORP. Lexington, MA · 2009
Prevention Pharmaceuticals, Inc. New Haven, CT · 2011
Mira Dx, Inc. New Haven, CT · 2009
ACHILLION PHARMACEUTICALS INC New Haven, CT · 2010
SAMARA INNOVATIONS LLC New Haven, CT · 2010
ANCORA PHARMACEUTICALS INC Medford, MA · 2009
PROTEIN FOREST, INC. Lexington, MA · 2009

A shared address can mean the same team, a shared office building or a registered agent. It is a lead, not a conclusion.

Registrations and other filings

Adviser registration (Form ADV)

Not yet searched. Sources to be searched: SEC Investment Adviser Information Reports — Form ADV data for SEC-registered advisers and exempt reporting advisers (file dated 2026-10-02); SEC Investment Adviser Public Disclosure (IAPD) firm search — registered and exempt reporting advisers · Search queued. Results are added automatically; check back later.

Other offering types (Regulation A and Regulation Crowdfunding)

None found in sources searched.

Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.

Look further

One-tap searches on sites we do not index ourselves, with the name pre-filled (Cambridge, MA). Each opens in a new tab; what you find there is not verified by PartnerFacts.

Change history

No corrections have been requested for this page.

Every fact links to its public-record source. Plain-English notes next to a fact are our reading of that fact, not a rating. Request a correction · Facts policy

Request a correction

Free. Logged with status: received → under review → fixed / confirmed with source.

Add a response

If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.

Monitor this person

Members get an email when Jonathan Fleming appears on a new Form D, or when a court case or SEC action is matched to them. See plans →

Jonathan Fleming

The short version

What the community is saying

Key records

1. Lawsuits

2. Regulatory actions

3. Bankruptcies

4. Differences between public sources

5. Money to insiders

Deals 15

People around Jonathan 40

The team behind the deals

28 other issuers file from the same address

Registrations and other filings

Adviser registration (Form ADV)

Other offering types (Regulation A and Regulation Crowdfunding)

Look further

Social and web

Courts

Securities regulators

Business registries

Change history

Request a correction

Add a response

Monitor this person